

Pathogenics, Inc.

“Fighting Infections to Protect Our Future”

CORPORATE SUMMARY

Pathogenics, Inc. is a biopharmaceutical company that acquires and develops new therapeutic drugs that have large sales potential (>\$1 billion/yr) and target unmet medical needs. We are currently developing a broad-spectrum anti-infective drug called N-Chlorotaurine for topical and body cavity infections. This drug may safely treat multiple infections - many which have very large markets, and few, if any, satisfactory drug treatments.

The Company in-licenses its experimental drugs, demonstrates they work in small-scale human clinical trials, and then partners with large pharmaceutical companies who are seeking new drugs to fill their product pipelines. These partners then complete larger-scale clinical trials, obtain US FDA new drug approval, and market the drugs worldwide. This business strategy is designed to minimize fixed costs, add significant value to our experimental drugs, and accelerate the time to corporate profitability.

PATHOGENICS PRODUCT PORTFOLIO

Product	Indications/Applications	Development Stage	Market
NCT Anti-Infective	<ul style="list-style-type: none"> • Sinusitis • Conjunctivitis (Pink Eye) • Otitis (Swimmers Ear) • Skin Ulcers • All Infections 	<ul style="list-style-type: none"> • Phase IIA, 12 patients • Phase IIB, 60 patients • Phase IIB, 50 patients • Phase IIB, 40 patients • Potential Indications 	<ul style="list-style-type: none"> • \$2.2 billion/yr (U.S.) • 15% of population • 30 million people (U.S.) • \$3.3 billion/yr (world) • \$45 billion/yr (world)

KEY PATHOGENICS INVESTMENT POINTS

- **Billion Dollar Market Opportunities** with unmet medical needs such as anti-infective therapies that do not promote drug resistance, and neurological disorders such as Parkinson’s Disease
- **Diversified Drug Portfolio** increases the chance of having a successful drug and reduces investment risk
- **In-Licensing and Big Pharma Partnering** minimizes fixed costs and accelerates the time to profitability
- **Clear Exit Strategy** first shows the drugs work effectively in humans, then partners with large pharmaceutical companies to perform larger trials, obtains new drug approval and markets them worldwide
- **Experienced Management Team** with proven track records in developing and licensing new drugs

COMPANY INFORMATION

EXECUTIVE OFFICERS

Frederic P. Zotos, Esq.
President and CEO

Michael L. Ferrari
VP Research & Business Development

CORPORATE OFFICES

99 Derby Street, Suite 200, Hingham, MA 02043, Phone: 781-556-1090

HOMEPAGE

www.pathogenics.com

STOCK EXCHANGE

N/A

Some of the information on this fact sheet may contain projections or other forward-looking statements regarding future events or the future financial performance of Pathogenics Inc. We wish to caution you that these statements are only predictions and that actual events or results may differ materially from those predicted in these statements. We refer you to the documents the Pathogenics files from time to time with the Securities and Exchange Commission, specifically Pathogenics' most recent Form 10-KSB and Form 10-QSB. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in our projections or forward-looking statements. © 2007 Pathogenics, Inc. All rights reserved.

The Drug Resistance Challenge

Drug-resistant infections – those that are not killed or inhibited by anti-infective drugs – are an increasingly important public health concern. More than two-thirds of the bacterial infections acquired in U.S. hospitals and about half of the common bacterial infections in outpatients do not respond to at least one of the antibiotics that used to work, and many physicians are concerned that several bacterial infections soon may be untreatable. Anti-infectives are the third largest segment of the pharmaceutical industry, with annual worldwide sales totaling \$45 billion, and a strong growth rate. Broad-spectrum, multi-indication anti-infective drugs generally have potential annual sales of \$1 billion within three years of market introduction.

Topical and body cavity infections are a major therapeutic area for application of anti-infectives, and require local application of the drug to kill the infection. Treatment of sinusitis and ear infections are the first and second most common reasons for antibiotic prescriptions, and the culprit, *Streptococcus pneumoniae*, is more likely to be resistant than any other common bacteria. Conjunctivitis is the most common eye problem seen by primary care physicians, and there is presently no approved drug treatment for viral conjunctivitis.

The NCT Opportunity

N-chlorotaurine, or NCT, is a novel, anti-infective compound that is exceptionally safe and tolerable. After the drug kills the infection, it quickly breaks down into natural substances already found in the human body, and therefore it is non-toxic and does not cause allergic reactions. NCT is effective against a broad-spectrum of infections including both bacteria, viruses and fungi, and destroys virtually all pathogens. Unlike antibiotics, the way it kills pathogens prevents them from ever becoming resistant to the drug.

NCT has recently been shown to work effectively in several small-scale Phase II human clinical studies, including sinusitis, otitis externa (“swimmers ear”), viral conjunctivitis (“pink eye”), and skin ulcers. The inventors from the University of Innsbruck, Austria, are currently continuing their ongoing clinical research of the drug in several additional indications. The Company plans to submit an Investigational New Drug application to the FDA, and eventually partner the drug with several companies for various indications.